Skip to search formSkip to main contentSkip to account menu

MK-7009

Known as: MK 7009, MK7009 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Background Some drugs that are actively taken up into the liver exhibit greater than dose proportional increases in plasma… 
Highly Cited
2012
Highly Cited
2012
A highly efficient synthesis of Vaniprevir (MK-7009) has been accomplished in nine linear steps and 55% overall yield. The key… 
Highly Cited
2012
Highly Cited
2012
Vaniprevir (MK‐7009) is a macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. The aim of the… 
2011
2011
Development of a practical synthesis of MK-7009, a 20-membered [corrected] macrocycle, is described. A variety of ring-closing… 
Highly Cited
2011
Highly Cited
2011
BACKGROUND & AIMS The hepatitis C virus (HCV) genotype influences efficacy of interferon (IFN)-based therapy. HCV protease… 
Highly Cited
2010
Highly Cited
2010
A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a molecular… 
Highly Cited
2010
Highly Cited
2010
ABSTRACT In order to assess the natural variation in susceptibility to hepatitis C virus (HCV) NS3 protease inhibitors (PIs… 
Highly Cited
2010
Highly Cited
2010
ABSTRACT Efforts to develop novel, interferon-sparing therapies for treatment of chronic hepatitis C (HCV) infection are… 
Highly Cited
2009
Highly Cited
2009
ABSTRACT The administration of hepatitis C virus (HCV) NS3/4A protease inhibitors to patients with chronic HCV infections has…